Navigation Links
Destined for disease: Breast cancer mutation regulates cell fate
Date:2/3/2011

A new study sheds light on why individuals who inherit a particular family of mutations have a high risk of developing a very aggressive form of breast cancer. The research, published by Cell Press on February 4th in the journal Cell Stem Cell, shows that breast tissue cells from these individuals make abnormal cell-fate decisions even before cancer develops and provides exciting new insights into the mechanisms behind one of the most lethal types of breast cancer.

There are many forms of human breast cancer. Mutations in the BRCA1 tumor suppressor gene are associated with the development of the "basal-like" subtype of breast cancer which exhibits a very poor prognosis. "Recent evidence has indicated that BRCA1 might regulate breast cell differentiation," explains senior study author Dr. Charlotte Kuperwasser, Associate Professor in anatomy and cellular biology from Tufts University School of Medicine and member of the Sackler School of Graduate Biomedical Sciences at Tufts. "We wanted to examine whether BRCA1's role in differentiation was associated with the increased development of basal-like breast cancer."

Dr. Kuperwasser's group examined disease-free breast tissues from patients with normal or mutant BRCA1 genes. Using an ingenious strategy that allowed them to mimic the environment of intact human breast tissue, they transplanted the human cells into mice and looked at the types of tumors that formed after the cells were exposed to additional cancer-promoting signals. Although the cells with normal BRCA1 grew into different kinds of breast cancer, the cells from women with BRCA1 mutations mostly formed the aggressive basal-like tumors. Importantly, molecular analysis of disease-free breast cells with mutated BRCA1 revealed that even before tumors developed, the mutant cells were more likely to remain immature and contain elevated levels of a protein called Slug. The researchers showed that when Slug is present in the breast, cells are unable to undergo proper maturation and are stalled in a premature state of development. This premature state of development is subsequently retained in basal-like breast cancers.

These findings show that BRCA1 mutations significantly impact breast cell maturation even before the patients manifest an increased risk for breast cancer. In a sense, the BRCA1 mutation "stacks the deck" towards a basal-like tumor phenotype by biasing differentiation towards this state. "Future studies will be necessary to fully dissect the precise domains and mechanisms by which BRCA1 regulates breast epithelial differentiation," concludes Dr. Kuperwasser. "In addition, further experiments will be needed to determine whether certain mutations in BRCA1 affect differentiation and regulate cell fate differently and whether different mutations alter the propensity for the development of basal-like tumors."


'/>"/>

Contact: Elisabeth Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related medicine news :

1. Shorter Sleep in Men Ups Risk of Heart Disease: Study
2. Air Pollution Ups Risk of Chronic Lung Disease: Study
3. Parkinsons disease: Excess of special protein identified as key to symptoms and possible new target for treatment with widely used anti-cancer drug imatinib
4. Chronic Lyme disease: How often is it diagnosed and treated?
5. HIV/AIDS treatment curbs spread of disease: UBC-BC CfE study
6. Crohn's & Colitis Foundation National Event Helping Women Manage Inflammatory Bowel Disease: Two Women Physician Experts and Researchers in IBD on Interactive Webcast/Teleconference
7. Patients at high risk of recurrences of heart disease: Breakthrough in prevention
8. Understanding causes of cancer and chronic disease: The Canadian Partnership for Tomorrow Project
9. Thyroid Disease: The Hidden Epidemic
10. Princeton scientists discover mechanism involved in breast cancers spread to bone
11. Breast cancer cells outsmart the immune system and thrive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... August 22, 2017 , ... Western North Carolina’s only certified ... international aesthetics conference for medical professionals about the positive impact Juliet™ feminine ... growing practice. , Dr. George K. Ibrahim shared the results of ...
(Date:8/22/2017)... ... August 22, 2017 , ... Nurses at Apple Rehab Watch Hill ... recently received training and certification in Closed Pulse Irrigation™ (CPI) for wound ... rating from the Centers for Medicare and Medicaid Services, to have a CPI machine ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Without ... abuse and neglect, and the struggles faced while hoping for a better life. ... published author, Judy Von Bernewitz, who spent 13 years working with deprived/neglected adolescents ...
(Date:8/22/2017)... ... 2017 , ... TopConsumerReviews.com recently gave a best-in-class 5-star rating to Energy NADH, ... stress of modern life continually makes more demands on time and energy, people are ... trap people in vicious high/low cycles and can also cause long term health issues. ...
(Date:8/21/2017)... ... August 22, 2017 , ... Nanoparticle research provides an ... safety. By learning and implementing best practices for containment using ventilated safety enclosures, ... will gain a better understanding of a method for safely testing nanotechnology hoods. ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Law and Gulf Coast Regional Blood Center to host a ... Mostyn Law family has had 3 members that needed blood ... Law is partnering with Gulf Coast Regional Blood Center of ... Blood supplies are running low. Gulf Coast Regional Blood Center,s inventory ... That is why the blood center reached out to Mostyn ...
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that its ... Inc., has recently opened a New York City Office in ... of its unique Topical Wound Oxygen (TWO 2 ) homecare therapy. ... Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS accreditation ... ...
(Date:8/8/2017)... 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical ... financial results for the second quarter ended June 30, ... quarter 2017 and to date: ... for the Company,s lead project, BL-8040: ... BL-8040 as novel stem cell mobilization treatment for autologous ...
Breaking Medicine Technology: